Evoq Remedies Limited: FY26 Loss Deepens, Auditor Raises Red Flags

Evoq Remedies reported a net loss of ₹0.251 crore for the fiscal year ended March 31, 2026. The company saw revenue from operations increase by 117% to ₹25.51 crore, up from ₹11.76 crore in the previous fiscal year.

Reader Takeaway: Revenue grew significantly but a widening loss and auditor concerns overshadow growth.

What just happened

Evoq Remedies Limited announced its audited financial results for FY 2025-26, reporting a net loss of ₹0.251 crore (₹25.10 lakh). This marks a significant shift from the previous fiscal year's profit of ₹0.13 crore (₹12.82 lakh). Despite a substantial 117% year-over-year revenue growth to ₹25.51 crore, total expenses of ₹27.01 crore outpaced revenues, leading to the net loss.

Why this matters

The company's financial health is under scrutiny due to the net loss and, more critically, the auditor's qualified opinion. This opinion highlights serious concerns, including loans to related parties without proper approval and unconfirmed balances for trade receivables and supplier advances. Furthermore, the auditor has raised a material uncertainty regarding the company's ability to continue as a going concern, indicating potential financial instability.

The backstory

In FY 2024-25, Evoq Remedies had reported a modest profit of ₹0.13 crore. The net worth of the company saw a marginal decrease of 0.54% in FY 2025-26, standing at ₹44.30 crore. The company is also facing active investigations by SEBI concerning the integrity of its financial statements and the utilization of funds raised via a preferential issue.

What changes now

Investors face heightened uncertainty. The qualified audit report and SEBI investigations necessitate close monitoring of the company's compliance, financial management, and operational strategy. The company's ability to address the auditor's concerns and the ongoing regulatory probes will be crucial for its future prospects.

Risks to watch

The primary risks include the potential write-off of unconfirmed receivables and advances, the impact of SEBI's findings, and the company's capacity to meet its outstanding statutory liabilities, which include significant amounts for GST, Income Tax, and TDS.

Peer comparison

Information on specific peers and their financial performance or audit reports is not provided in the filing.

Context metrics (time-bound)

• Revenue FY 2025-26: ₹25.51 crore (up 117% YoY).
• Net Loss FY 2025-26: ₹0.251 crore.
• Related Party Loans: ₹6.70 crore.
• Unconfirmed Trade Receivables: ₹3.85 crore.
• Unconfirmed Supplier Advances: ₹12.51 crore.
• Outstanding Income Tax: ₹1.88 crore.
• Outstanding GST Demands: ₹6.55 crore.

What to track next

Investors should closely monitor the outcomes of the SEBI investigations, the company's progress in reconciling balances and regularizing statutory dues, and any further updates on the going concern status.